Our Intelligence is Not Artificial
The AMCP Research Institute advances research that strengthens managed care pharmacy, informs coverage and policy decisions, and improves patient access and outcomes. We support rigorous, data-driven work that helps you navigate emerging therapies, evolving regulations, and increasingly complex benefit design. AMCP Research Institute (ARI) includes the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC).
Where We Came From
BBCIC is a collaborative research initiative focused on real-world evidence and biologic and biosimilar outcomes. It's mission is to generate reliable real-world evidence that examines the safety and effectiveness of biologics in order to improve public health. AMCP established BBCIC in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars, and other related products.
Past & Future Research Projects
To date, the BBCIC has:
- Published 18 manuscripts.
- Presented 54 posters at major health care conferences.
- Created 4 research reports.
- Presented 40 podium and invited presentations.
Grant Programs
We are hard at work! Here are some FDA grants in motion:
- FDA Grant U01FD007757: $1,311,368 – Improving the Efficiency of Regulatory Decisions for Biosimilar and Interchangeable Biosimilars by Leveraging Real-World Data
- FDA Grant U01FD008041: $1,452,600 – Bridging the Gap: Using Foreign RealWorld Data to Inform Interchangeable Biosimilar Approvals
Where We Are Now
Leverage the Power of AMCP
AMCP members improve the lives of nearly 300 million Americans served by health plans, pharmacy benefit management firms and emerging care model.
- Treatment and coverage decisions.
- Advance and demonstrate value of managed care pharmacy.
- Improve public health.
ARI is an avenue for AMCP to create even more tools and resources to support the important work of our members.
You can support our research by donating to the AMCP Foundation, the charitable arm of AMCP, dedicated to advancing the future of managed care pharmacy by investing in education and philanthropy to advance the profession and accessibility of patient care
Where We Are Going
Projects in the Works
- The Effect of the Covid-19 Pandemic on non-Covid Related Treatment and Outcomes in Inflammatory Bowel Disease
- Adherence – Algorithms, Methods and Best Practices using Claims Data
- Biosimilar Access and Utilization
- Anti-VEGF (oncology/opthamlogy) and Bone Antiresorptive Therapy Landscape Assessment
- Patient Experiences with Biologics and Biosimilars for IBD: A Qualitative Study
- Survey of Biosimilar Market Sustainability
- Quantifying the impact of utilization management tools (e.g., prior authorization) on patient access, outcomes, and cost of care
- Developing an abbreviated dossier format for biosimilars (in collaboration with the AMCP Professional Affairs team)
Released
- Real-World Evidence Initiative – As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards which were released in JMCP in September, 2025.
